



**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

<b>Attorney Docket Number</b>	4239-67020-02
<b>Application Number</b>	10/534,626
<b>Filing Date</b>	May 11, 2005
<b>First Named Inventor</b>	Finkel
<b>Art Unit</b>	1616
<b>Examiner Name</b>	Not yet assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
/SK/		DIMRI <i>et al.</i> , "A biomarker that identifies senescent human-cells in culture and in aging skin in-vivo," <i>Proc.Natl. Acad Sci.U.S.A.</i> 92:9363-9367, 1995
		GEIGER, "The aging of lympho-hematopoietic stem cells," <i>Nature Immunology</i> 3:329-333, 2002
		ITO <i>et al.</i> , "Endothelial progenitor cells as putative targets for angiostatin," <i>Cancer Res</i> 59:5875-5877, 1999
		KAUSHAL <i>et al.</i> , "Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo," <i>Nature Med</i> 7:1035-1040, 2001
		LIN <i>et al.</i> , "Origins of circulating endothelial cells and endothelial outgrowth from blood," <i>J Clin Invest</i> 105:71-77, 2000
		PEICHEV <i>et al.</i> , "Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors," <i>Blood</i> 95:952-958, 2000
		REYES <i>et al.</i> , "Origin of endothelial progenitors in human postnatal bone marrow," <i>J Clin Invest</i> 109:337-346, 2002
		TAKAHASHI <i>et al.</i> , "Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization," <i>Nat Med</i> 5:434-438, 1999
		WALTER <i>et al.</i> , "Statin therapy accelerates reendothelialization. A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells," <i>Circulation</i> 3017-3024, 2002
/SK/		WERNER <i>et al.</i> , "Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes," <i>N Engl J Med</i> 353:999-1007, 2005

<b>EXAMINER SIGNATURE:</b> /Sumesh Kaushal/ (10/24/2007)	<b>DATE CONSIDERED:</b>
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

10/534626

SAS:jam 05/11/05 4239-67020-02 382016 E-037-2003/1-US-02

EXPRESS MAIL LABEL NO.: EV510808780US

JC14 Rec'd FCT/PTO 11 MAY 2005

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Attorney Docket Number	4239-67020-02
Application Number	To be assigned
Filing Date	To be assigned
First Named Inventor	Toren Finkel
Art Unit	To be assigned
Examiner Name	To be assigned

## **U.S. PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
/SK/		4,403,041	06 Sept 1983	Bürk et al.
/SK/		6,156,500	05 Dec 2000	Falb

## **FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

## **OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
/SK/		Asahara et al., <i>Science</i> 275:964-967, 1997
		Asahara et al., <i>Circulation Research</i> 85:221-228, 1999
		Asahara et al., <i>The EMBO Journal</i> 18(14):3964-3972, 1999
		Bahlmann et al., <i>Blood</i> 103(3):921-926, 2004
		Dimmeler et al., <i>The Journal of Clinical Investigation</i> 108(3):391-397, 2001
		Eizawa et al., <i>Current Medical Research and Opinion</i> 19(7):627-633, 2003
		Gokce et al., <i>Circulation</i> 105:1567-1572, 2002
↓ /SK/		Grant et al., <i>Nature Medicine</i> 8(6):607-612, 2002

EXAMINER SIGNATURE: /Sumesh Kaushal/ (10/24/2007)

DATE CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/534626

SAS:jam 05/11/05 4239-67020-02 38706 E-037-2003/I-US-02

EXPRESS MAIL LABEL NO.: EV510808780US

JCT Rec'd PCT/PTO 11 MAY 2005

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	4239-67020-02
		Application Number	To be assigned
		Filing Date	To be assigned
		First Named Inventor	Toren Finkel
		Art Unit	To be assigned
		Examiner Name	To be assigned
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>OTHER DOCUMENTS</b>	
/SK/		Halcox et al., <i>Circulation</i> 106:653-658, 2002	
		Hill et al., <i>The New England Journal of Medicine</i> 348(7):593-600, 2003	
		Kalka et al., <i>Circulation Research</i> 86:1198-1202, 2000	
		Kocher et al., <i>Nature Medicine</i> 7(4):430-436, 2001	
		Llevadot et al., <i>The Journal of Clinical Investigation</i> 108(3):399-405, 2001	
		Luttun et al., <i>Trends Cardiovasc Med</i> 12(2):88-96, 2002	
		Murohara et al., <i>The Journal of Clinical Investigation</i> 105(11):1527-1536, 2000	
		Perticone et al., <i>Circulation</i> 104:191-196, 2001	
		Powell et al., <i>Arterioscler Thromb Vasc Biol.</i> 25:296-301, 2005	
		Schächinger et al., <i>Circulation</i> 101:1899-1906, 2000	
		Seiler et al., <i>Circulation</i> 104:2012-2017, 2001	
		Shintani et al., <i>Circulation</i> 103:2776-2779, 2001	
		Suwaidi et al., <i>Circulation</i> 101:948-954, 2000	
		Vasa et al., <i>Circulation Research</i> . 89:e1-e7, 2001	
↓ /SK/		Vasa et al., <i>Circulation</i> 103:2885-2890, 2001	

<b>EXAMINER SIGNATURE:</b> /Sumesh Kaushal/ (10/24/2007)	<b>DATE CONSIDERED:</b>
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	